FOLFOX Chemotherapy
Treatment for Stomach Cancer
Typical Dosage: Standard BSA-based regimen (Oxaliplatin 85mg/m2, Leucovorin 400mg/m2, 5-FU 400mg/m2 bolus + 2400mg/m2 infusion over 46h, bi-weekly)
Effectiveness
75%
Safety Score
25%
Clinical Trials
65
Participants
25K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Standard BSA-based regimen (Oxaliplatin 85mg/m2, Leucovorin 400mg/m2, 5-FU 400mg/m2 bolus + 2400mg/m2 infusion over 46h, bi-weekly)
Time to Effect
2-4 weeks
Treatment Duration
6 months (adjuvant) or until progression (palliative)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
3(Treat 3 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$20,000
Monitoring:$10,000
Side Effect Mgmt:$15,000
Total Annual:$45,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$110,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$112,500
Cost per Remission
$450,000
FOLFOX Chemotherapy Outcomes
for Stomach Cancer
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+40%
Remission Rate
+10%
Common Side Effects
Nausea/Vomiting
+70%
Neutropenia
+60%
Peripheral neuropathy (Oxaliplatin)
+70%
Diarrhea
+50%
Fatigue
+80%
Mucositis
+40%
Sources:
Active Clinical Trials
7 active trials recruiting for FOLFOX Chemotherapy in Stomach Cancer
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
NCT04421820RECRUITINGPHASE1, PHASE2
220 participants
INTERVENTIONAL
Santa Monica, United States +23 more
Started: Aug 28, 2020
sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
NCT05332002RECRUITINGPHASE2
38 participants
INTERVENTIONAL
Hamilton, United States +5 more
Started: Jul 13, 2022
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
NCT07070466RECRUITINGPHASE2
40 participants
INTERVENTIONAL
Santa Monica, United States +1 more
Started: Oct 10, 2025
TAIC FOLFOX for Locally Advanced G/GEJA
NCT07655024RECRUITINGPHASE2
31 participants
INTERVENTIONAL
Beijing, China
Started: Nov 1, 2025
PIPAC in Multimodal Therapy for Patients with Oligometastatic Peritoneal Gastric Cancer
NCT05303714RECRUITINGPHASE3
98 participants
INTERVENTIONAL
Verona, Italy
Started: Mar 31, 2022
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
NCT06663319RECRUITINGPHASE1
260 participants
INTERVENTIONAL
Tucson, United States +11 more
Started: Oct 15, 2024
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
NCT06846346RECRUITINGPHASE2
88 participants
INTERVENTIONAL
Lyon, France +3 more
Started: Nov 20, 2025
Completed Clinical Trials
9 completed trials for FOLFOX Chemotherapy in Stomach Cancer
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
NCT03662659COMPLETEDPHASE2
274 participants
INTERVENTIONAL
Clovis, United States +78 more
Started: Oct 16, 2018
BReast CAncer Genes(BRCA) Expressions in Metastatic Gastric Cancer
NCT03838406COMPLETEDNA
30 participants
INTERVENTIONAL
Seoul, South Korea
Started: Aug 1, 2017
PIPAC and FOLFOX for Gastric Cancer Peritoneal Cancer
NCT05644249COMPLETEDNA
37 participants
INTERVENTIONAL
Vilnius, Lithuania +1 more
Started: Dec 1, 2022
FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
NCT00673673COMPLETEDPHASE2
39 participants
INTERVENTIONAL
Hamden, United States +1 more
Started: May 1, 2008
Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy
NCT04526886COMPLETEDNA
52 participants
INTERVENTIONAL
Lebanon, United States
Started: Oct 15, 2020
S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma
NCT01364376COMPLETEDNA
583 participants
INTERVENTIONAL
Jinan, China +7 more
Started: Jun 1, 2011
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
NCT00982592COMPLETEDPHASE2
124 participants
INTERVENTIONAL
Sacramento, United States +29 more
Started: Sep 1, 2009
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
NCT03597581COMPLETEDPHASE1
89 participants
INTERVENTIONAL
Prescott Valley, United States +16 more
Started: Jun 5, 2018
FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
NCT01913639COMPLETEDPHASE2
39 participants
INTERVENTIONAL
Basking Ridge, United States +4 more
Started: Jul 1, 2013
Showing 20 of 76 total trials